ABNOM
☆ ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ.
References
ເລເຊີ Q-switched Nd:YAG ເປັນທີ່ຮູ້ຈັກໃນການປິ່ນປົວ nevus ຂອງ Ota ແລະເງື່ອນໄຂທີ່ຄ້າຍຄືກັນ. ພວກເຮົາໄດ້ເຮັດການສຶກສາເພື່ອເບິ່ງວ່າເລເຊີ high-fluence 1064 nm Q-switched Nd:YAG ເຮັດວຽກໄດ້ດີພຽງໃດໃນບໍລິເວນທີ່ຜິດປົກກະຕິຂອງມົງໂກນ, ໂດຍບໍ່ເຮັດໃຫ້ຜິວໜັງອ່ອນລົງ. ພວກເຮົາໄດ້ສຶກສາຄົນເຈັບ 61 ຄົນທີ່ມີຈຸດເຫຼົ່ານີ້, ກວດເບິ່ງທັງຫມົດ 70 ບາດແຜ. ເຄິ່ງຫນຶ່ງຂອງ lesions ໄດ້ຮັບການປິ່ນປົວດ້ວຍ laser, ໃນຂະນະທີ່ຄົນອື່ນໄດ້ຖືກປະໄວ້ໂດຍບໍ່ມີການປິ່ນປົວສໍາລັບການປຽບທຽບ. ພວກເຮົາໄດ້ປະເມີນຜົນໄດ້ໂດຍການນໍາໃຊ້ມາດຕະຖານແລະອຸປະກອນທີ່ເອີ້ນວ່າ Mexameter® ເພື່ອວັດແທກລະດັບ melanin. ຄົນເຈັບໄດ້ຖືກຕິດຕາມໂດຍສະເລ່ຍ 14 ເດືອນໃນກຸ່ມການປິ່ນປົວແລະ 18 ເດືອນໃນກຸ່ມສັງເກດການ. ໃນຕອນທ້າຍຂອງການສຶກສາ, ພວກເຮົາໄດ້ພົບເຫັນຄວາມແຕກຕ່າງທີ່ສໍາຄັນຂອງຄະແນນຂະຫນາດແລະລະດັບ melanin ລະຫວ່າງກຸ່ມທີ່ໄດ້ຮັບການປິ່ນປົວແລະບໍ່ໄດ້ຮັບການປິ່ນປົວ, ໂດຍກຸ່ມທີ່ໄດ້ຮັບການປິ່ນປົວດ້ວຍ laser ສະແດງໃຫ້ເຫັນຜົນໄດ້ຮັບທີ່ດີກວ່າ. High-fluence Q-switched Nd:YAG laser, ໂດຍບໍ່ມີການເຮັດໃຫ້ຜິວຫນັງສະຫວ່າງ, ພິສູດໄດ້ປະສິດທິພາບແລະປອດໄພສໍາລັບການປິ່ນປົວຈຸດທີ່ຜິດປົກກະຕິຂອງມົງໂກນເຫຼົ່ານີ້.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
ພວກເຮົາໄດ້ສຶກສາປະສິດທິຜົນແລະຄວາມປອດໄພຂອງການນໍາໃຊ້ການປິ່ນປົວ laser ສະເພາະສໍາລັບ ABNOM , ແລະເບິ່ງວ່າປັດໃຈໃດທີ່ອາດຈະມີຜົນກະທົບວິທີການເຮັດວຽກໄດ້ດີ. ພວກເຮົາໄດ້ເບິ່ງຄົນເຈັບ 110 ຄົນທີ່ມີ ABNOM ແລະໄດ້ຮັບການປິ່ນປົວລະຫວ່າງສອງຫາເກົ້າເລເຊີ. ພວກເຮົາໄດ້ພົບເຫັນວ່າການປິ່ນປົວໄດ້ຜົນດີຂຶ້ນໃນເວລາທີ່ມັນເຮັດໄດ້ດົນກວ່າ, ແຕ່ບໍ່ແມ່ນເຊັ່ນດຽວກັນກັບຄົນເຈັບທີ່ສູງອາຍຸ. ມັນຍັງເຮັດວຽກໄດ້ດີກວ່າໃນຄົນເຈັບທີ່ມີຜິວຫນັງອ່ອນກວ່າ (ປະເພດ III) ແລະພື້ນທີ່ທີ່ຖືກກະທົບຂະຫນາດນ້ອຍກວ່າ (ຫນ້ອຍກວ່າ 10 cm2) . ການມີ melasma ພ້ອມກັບ ABNOM ເຮັດໃຫ້ການປິ່ນປົວປະສິດທິພາບຫນ້ອຍລົງ. ສີ ຫຼືຈຳນວນຂອງພື້ນທີ່ທີ່ຖືກກະທົບເບິ່ງຄືວ່າບໍ່ມີຄວາມແຕກຕ່າງ. ປະມານ 10% ຂອງຄົນເຈັບມີຈຸດດ່າງດໍາຫຼັງຈາກການປິ່ນປົວ. ການປິ່ນປົວຫຼາຍໆຄັ້ງກ່ອນໄວໃຫ້ຜົນໄດ້ຮັບທີ່ດີ. ຄົນເຈັບທີ່ມີອາຍຸແກ່ທີ່ມີຜິວຫນັງຊ້ໍາແລະຈຸດດ່າງດໍາແມ່ນມັກຈະເປັນຈຸດດ່າງດໍາຫຼັງຈາກການປິ່ນປົວ. ສໍາລັບຄົນເຈັບທີ່ມີ ABNOM ແລະ melasma, ມັນດີກວ່າທີ່ຈະໃຊ້ເລເຊີທີ່ມີພະລັງງານຕ່ໍາເພື່ອຫຼີກເວັ້ນການເຮັດໃຫ້ melasma ຮ້າຍແຮງຂຶ້ນ.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ ການປິ່ນປົວ
ຕົວແທນ whitening ບໍ່ຄ່ອຍຊ່ວຍ. ບໍ່ເຫມືອນກັບ melasma, ABNOM ສາມາດໄດ້ຮັບການປັບປຸງດ້ວຍການປິ່ນປົວດ້ວຍເລເຊີແລະປະໄວ້ເພື່ອເອົາອອກໂດຍບໍ່ມີການເກີດໃຫມ່. ການປິ່ນປົວເລເຊີສາມາດປະຕິບັດໄດ້ 10 ຫາ 20 ເທື່ອເພື່ອປິ່ນປົວ ABNOM.
#QS1064 laser